SCHEMBL5636282

SCHEMBL5636282

Clc1cccc(-c2cc3c4c(c2)[C@@H]2CNCC[C@@H]2N4CCCO3)c1Cl

nearest known ligand 0.46

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
HTR2C P28335 8/20 0.46
HTR2A P28223 4/20 0.43
HTR2B P41595 3/20 0.43
HTR6 P50406 2/20 0.35
CNR2 P34972 5/20 0.33
PDCD1 Q15116 1/20 0.32
CD274 Q9NZQ7 1/20 0.32
SLC6A2 P23975 2/20 0.31
SLC6A4 P31645 2/20 0.31
SLC6A3 Q01959 2/20 0.31
KCNH2 Q12809 1/20 0.31
CYP2D6 P10635 1/20 0.31
CNR1 P21554 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5637932 0.94 HTR2C (0.43) HTR2CHTR2AHTR2BHTR6CNR2
SCHEMBL5636401 0.92 HTR2C (0.45) HTR2CHTR2AHTR2BHTR6KCNH2
SCHEMBL5636363 0.86 HTR2C (0.42) HTR2CHTR2AHTR2BCNR2SLC6A2
SCHEMBL5636451 0.86 HTR2C (0.51) HTR2CHTR2AHTR2B
SCHEMBL5635487 0.85 HTR2C (0.45) HTR2CHTR2AHTR2B
SCHEMBL5405373 0.83 HTR2C (0.57) HTR2CHTR2AHTR2BCNR2SLC6A2
SCHEMBL5416873 0.83 HTR2C (0.57) HTR2CHTR2AHTR2BCNR2SLC6A2
SCHEMBL5637062 0.83 HTR2C (0.43) HTR2CHTR2AHTR2BSLC6A2SLC6A4
SCHEMBL5637783 0.83 HTR2C (0.49) HTR2CHTR2AHTR2BHTR6KCNH2
SCHEMBL5637404 0.83 HTR2C (0.48) HTR2CHTR2AHTR2BHTR6KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE39679-E1 Substituted heterocycle fused gamma-carbolines BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2007-06-05 US disclosed
US-6713471-B1 SUCH AS TERT-BUTYL-1-METHYL-6,7,9,12-TETRAHYDRO-5H-PYRIDO-(4,3-B)(1,4) THIAZEPINO(2,3,4-HI)INDOLE-11(10H)-CARBOXYLATE; SEROTONIN AGONISTS AND ANTAGONISTS; CENTRAL NERVOUS SYSTEM DISORDERS BRISTOL-MYERS SQUIBB PHARMA COMPANY 2004-03-30 US disclosed